Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGPhase 2INTERVENTIONAL

Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD)

Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD) in a Multi-center, Double-Blinded, Placebo-controlled Trial

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Intranasal nasal steroid sprays are the mainstay of treatment for chronic Eustachian tube dysfunction despite having little supportive evidence in the literature. A novel, commercially available nasal spray delivery system is available now for fluticasone that improves its delivery to the nasopharynx. The hypothesis of this study is that fluticasone using the novel spray system is effective for Eustachian tube dysfunction (ETD).

Who May Be Eligible (Plain English)

Who May Qualify: - Age greater than or equal to 18 years old, \<80 years old - Chronic Eustachian tube dysfunction defined as: - Symptoms in one or both ears \> 3 months AND - ETDQ-7 score \>14.5 AND - Type B, C, or As tympanometry - Female subjects of childbearing potential must have a negative urine pregnancy test at screening and throughout the study duration. Who Should NOT Join This Trial: - Age \<18 years old - Known history of otologic surgery (excluding myringotomy or myringotomy tubes) - Use of any additional intranasal medication - Tympanic membrane perforation - Adhesive otitis media - Cholesteatoma or significant retraction pocket - Middle ear effusion - Nasopharyngeal tumor - Any history of head and neck cancer - Any history of head and neck irradiation - Any history of temporomandibular disorder or prior surgery to the temporomandibular joint - Any medical condition that the investigator deems inappropriate for enrollment Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Age greater than or equal to 18 years old, \<80 years old * Chronic Eustachian tube dysfunction defined as: * Symptoms in one or both ears \> 3 months AND * ETDQ-7 score \>14.5 AND * Type B, C, or As tympanometry * Female subjects of childbearing potential must have a negative urine pregnancy test at screening and throughout the study duration. Exclusion Criteria: * Age \<18 years old * Known history of otologic surgery (excluding myringotomy or myringotomy tubes) * Use of any additional intranasal medication * Tympanic membrane perforation * Adhesive otitis media * Cholesteatoma or significant retraction pocket * Middle ear effusion * Nasopharyngeal tumor * Any history of head and neck cancer * Any history of head and neck irradiation * Any history of temporomandibular disorder or prior surgery to the temporomandibular joint * Any medical condition that the investigator deems inappropriate for enrollment

Treatments Being Tested

DRUG

Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray

Patients will use two sprays in each nostril twice a day for 6 weeks and additional 6 weeks (open label).

OTHER

Placebo Nasal Spray

The Placebo is made of the following ingredients: Purified Water, Microcrystalline Cellulose RC-591, Dextrose, Anhydrous, EDTA Disodium Dihydrate, Benzalkonium Chloride Solution 50%, Polysorbate 80 (Tween 80, HP-LQ-(MH)), Sodium Hydroxide, and Hydrochloric Acid. Patients will use two sprays in each nostril twice a day

Locations (4)

Cedars-Sinai Medical Center
Los Angeles, California, United States
Sacramento Ear, Nose & Throat
Sacramento, California, United States
Indiana University
Indianapolis, Indiana, United States
Ochsner Health System
New Orleans, Louisiana, United States